Sharekhan's research report on Gland Pharma
Gland is an established player in Injectables space and is well-placed to harness the growth opportunities in this space. It has a strong compliance record with nil observations from the USFDA across all its plants. Gland has a unique B2B business model, which enables it grow its market share while maintaining cost leadership. Strong domain expertise, robust growth prospects, sturdy & consistent earnings track record, and healthy return ratios make Gland an ideal long-term investment pick.
Outlook
We Initiate coverage on Gland Pharma Limited (Gland) with a Buy recommendation and a price target of Rs. 3,040.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.